Anticardiolipin antibody
EstablishedAnticardiolipin antibody is one of three tests used together to classify antiphospholipid syndrome.
This antibody is tested alongside two others to diagnose antiphospholipid syndrome, a clotting disorder. Newer 2023 criteria changed exactly how doctors weigh the different antibody results together.
Anticardiolipin antibodies target cardiolipin, a phospholipid, and are one of three antiphospholipid antibodies (with anti-β2GP1 and lupus anticoagulant) used to classify antiphospholipid syndrome (APS).
Medium-to-high titer IgG or IgM anticardiolipin, combined with a qualifying clinical event (thrombosis or pregnancy morbidity), supports an APS diagnosis; low titers or isolated positivity without clinical correlation are less specific.
Measured via ELISA; the 2023 ACR/EULAR APS classification criteria revised how anticardiolipin, anti-β2GP1, and lupus anticoagulant are weighted together, changing diagnostic thresholds compared to older criteria.
Persistent, medium-to-high titer anticardiolipin positivity in a patient with prior thrombosis typically guides long-term anticoagulation therapy decisions and pregnancy management protocols.
Requires a qualifying clinical thrombotic or pregnancy event alongside positive serology for diagnosis.
- 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.